ALZ-801 promotes amyloid clearance from brain
Alzheon publication: Tolar (2024) Int J Mol Sci
Amyloid oligomers drive neurotoxicity & tau pathology
Injured neurons release misfolded tau protein that aggregates into tangles
Amyloid clearance from brain to plasma via astrocyte end-feet on capillaries & by glial uptake
Tarasof-Conway (2015) Nat Rev Neurol; Bagheri (2013) PLOS One
Valiltramiprosate blocks amyloid aggregation in brain, promotes efflux of monomers to plasma & activation of astrocytes
Tarasof-Conway (2015) Nat Rev Neurol & Bagheri (2013) PLOS One
Assay to measure neurotoxic amyloid oligomers in brain
- Alzheon collaborates with Czech Institute of Organic Chemistry & Biochemistry to develop commercial assay to measure neurotoxic amyloid oligomers in brain
- Diagnostic & theragnostic assay enables early intervention with valiltramiprosate
- Measurement of brain oligomer burden enables treatment & prevention:
- Monitoring of progress & assessment of treatment impact in patients
- Intervention years before emergence of clinical symptoms in cognitively normal individuals with increased risk for Alzheimer’s
Mass spectrometry detects soluble amyloid oligomers